Incyte cuts early-stage cancer drug to focus on next-gen programs
Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
Investors are focused on Incyte’s late-stage programs as the biotech braces for the 2028 patent cliff of its leading product Jakafi.
comments(0)
5-min edit window · permanent after that